Correction: Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung Metastases

Chan, Nancy; Willis, Amy; Kornhauser, Naomi; Ward, Matthew; Lee, Sharrell B.; Nackos, Eleni; Seo, Bo Ri; Chuang, Ellen; Cigler, Tessa; Moore, Anne; Donovan, Diana; Cobham, Marta Vallee; Fitzpatrick, Veronica; Schneider, Sarah; Wiener, Alysia; Guillaume-Abraham, Jessica; Aljom, Elnaz; Zelkowitz, Richard; Warren, Joel; Lane, Maureen E.; Fischbach, Claudia; Mittal, Vivek; Vahdat, Linda T.

doi:10.1158/1078-0432.ccr-20-3177

Cited by 8 publications

(9 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, ionophores for copper replenishment can induce cuproptosis. On the other approach for cancer, copper depletion could reduce the activity of angiogenic factors to suppress blood vessel development, and copper chelation has been recommended for cancer treatment due to its role as an antiangiogenic factor [ 37 ]. These findings suggested that therapies targeting cuproptosis might be a potential strategy for cancer.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Implication of a Cuproptosis-Related miRNA Signature in Hepatocellular Carcinoma

Jin

Wang

Meng

et al. 2022

Journal of Healthcare Engineering

View full text Add to dashboard Cite

Background. Hepatocellular carcinoma (HCC) is one of the most frequently diagnosed malignancies globally, accounting for the third cause of cancer mortality. Cuproptosis, a copper-induced cell death, was recently reported in Science. The purpose of this study was to evaluate the prognostic implication of cuproptosis-related miRNAs (CRMs) in HCC. Methods. Transcriptomic data and clinicopathological features of patients with HCC were extracted from the Cancer Genome Atlas (TCGA) database. Prognostic CRM signature was established by utilizing univariate Cox regression and LASSO analyses. To validate the accuracy of prediction, the Kaplan-Meier (K-M) and time-dependent receiver operating characteristic (ROC) analyses were adopted. A nomogram comprising clinical characteristics and the miRNA signature was developed to improve the prediction of patient outcomes. Finally, functional enrichment analysis and immune infiltration analysis were carried out. Results. Of CRMs, 14 were obtained to construct a prognostic miRNA signature. This CRM signature was an independent factor for predicting overall survival (OS). Kaplan-Meier curves demonstrated a noteworthy difference in survival rates between different risk subgroups ( p < 0.001 ). The robust prognostic capacity of this signature was exhibited by sampling verification and stratified survival analysis. Functional analysis indicated that the high-risk group was mainly enriched in signaling pathways and different levels of immune infiltration were revealed between the two risk groups. The potential interaction of the model with the immune checkpoint activities was also detected. Conclusion. The CRM signature could act as an independent predictor to guide individual treatment strategies, which could provide fundamental insights for further studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic Implication of a Cuproptosis-Related miRNA Signature in Hepatocellular Carcinoma

Jin

Wang

Meng

et al. 2022

Journal of Healthcare Engineering

View full text Add to dashboard Cite

show abstract

“…Various factors affecting PC cells include androgen deprivation, radiation, and chemotherapy (Haberkorn et al, 2016;Teo et al, 2019;Wang et al, 2021). In addition, tumor microenvironmental cells (TME) including mast cells, tumorassociated fibroblasts (CAFs), macrophages, and bone marrow stromal cells (BMSCs) have been shown to promote NED (Chan et al, 2017;Raphael et al, 2017;Ramnarine et al, 2018;Rooper et al, 2018;Su et al, 2018;Zhang et al, 2018).…”

Section: Discussionmentioning

confidence: 99%

Specific classification and new therapeutic targets for neuroendocrine prostate cancer: A patient-based, diagnostic study

Wang

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

Objective: Neuroendocrine prostate cancer (NEPC) is an aggressive variant of prostate cancer (PC) that may arise de novo or in patients previously treated with hormonal therapies for prostate adenocarcinoma as a mechanism of resistance. In our investigation, there appeared to be a strong correlation between neuroendocrine differentiation prostate cancer (NEDPC) and NEPC. The objectives of this study included exploring whether NEDPC is an intermediate stage in the progression of high-risk prostate cancer (HRPC) to NEPC and identifying risk factors and new targets associated with survival in the treatment of NEPC.Methods: The selected prostate cancer patients were progressed to high-risk and characterized by neuroendocrine. We collected the clinical data and characteristics of patients with three types of cancer: the incidence of metastasis, site and time of metastasis, recurrence rate, related treatment methods, etc. The similarity and differences of the three groups were compared through experiment and database.Results: By analyzing the clinical data and immunohistochemical results, we found that there seems to be a clinical feature of neuroendocrine differentiation (NED) status in between when patients progress from PC to NEPC. Finding novel treatment targets would therefore be beneficial by taking into account NEDPC as the stage of PC progression prior to NEPC. The metastasis-free survival curve and the immunohistochemical results are informing us that NEDPC can be a pre-state for diagnosing NEPC.Conclusion: NEPC is a late PC symptom that is frequently disregarded and has a bad prognosis. Finding novel treatment targets would therefore be beneficial by taking into account NEDPC as the stage of PC progression prior to NEPC.

show abstract

“…As a catalytic cofactor and a structural component of various proteins and enzymes, copper is indispensable for organisms, and its homeostasis is crucial for many physiological functions ( Denoyer et al, 2015 ; Setty et al, 2008 ; Bhattacharjee et al, 2017 ; Juloski et al, 2020 ; Shanbhag et al, 2019 ; Chan et al, 2020 ). Copper dysregulation and variations in copper metabolism-related proteins have been found in many tumors, including breast cancer ( Terada et al, 1999 ; Gupte and Mumper, 2009 ; Hlynialuk et al, 2015 ; Juloski et al, 2020 ).…”

Section: Discussionmentioning

confidence: 99%

“…The multifaceted effect of copper on carcinogenesis has been confirmed, it not only interrupts the initiation and progression of tumors but also promotes cell proliferation, angiogenesis, cell growth, and cell migration ( Brady et al, 2014 ; Angelé-Martínez et al, 2017 ; Lelièvre et al, 2020 ). Thus, copper chelators or ionophores that deplete or increase the copper level in tumors have been explored in preclinical studies, and been reported to have promising clinical value ( Chan et al, 2017 ; Xu et al, 2018 ; Chan et al, 2020 ; Cui et al, 2021 ).…”

Section: Discussionmentioning

confidence: 99%

Establishment and Validation of Prognostic Nomograms Based on Serum Copper Level for Patients With Early-Stage Triple-Negative Breast Cancer

Duan

Huang

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Background: Altered copper levels have been observed in several cancers, but studies on the relationship between serum copper and early-stage triple-negative breast cancer (TNBC) remain scare. We sought to establish a predictive model incorporating serum copper levels for individualized survival predictions.Methods: We retrospectively analyzed clinicopathological information and baseline peripheric blood samples of patients diagnosed with early-stage TNBC between September 2005 and October 2016 at Sun Yat-sen University Cancer Center. The optimal cut-off point of serum copper level was determined using maximally selected log-rank statistics. Kaplan-Meier curves were used to estimate survival probabilities. Independent prognostic indicators associated with survival were identified using multivariate Cox regression analysis, and subsequently, prognostic nomograms were established to predict individualized disease-free survival (DFS) and overall survival (OS). The nomograms were validated in a separate cohort of 86 patients from the original randomized clinical trial SYSUCC-001 (SYSUCC-001 cohort).Results: 350 patients were eligible in this study, including 264 in the training cohort and 86 in the SYSUCC-001 cohort. An optimal cut-off value of 21.3 μmol/L of serum copper was determined to maximally divide patients into low- and high-copper groups. After a median follow-up of 87.1 months, patients with high copper levels had significantly worse DFS (p = 0.002) and OS (p < 0.001) than those with low copper levels in the training cohort. Multivariate Cox regression analysis revealed that serum copper level was an independent factor for DFS and OS. Further, prognostic models based on serum copper were established for individualized predictions. These models showed excellent discrimination [C-index for DFS: 0.689, 95% confidence interval (CI): 0.621–0.757; C-index for OS: 0.728, 95% CI: 0.654–0.802] and predictive calibration, and were validated in the SYSUCC-001 cohort.Conclusion: Serum copper level is a potential predictive biomarker for patients with early-stage TNBC. Predictive nomograms based on serum copper might be served as a practical tool for individualized prognostication.

show abstract

Correction: Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung Metastases

Cited by 8 publications

References 1 publication

Prognostic Implication of a Cuproptosis-Related miRNA Signature in Hepatocellular Carcinoma

Prognostic Implication of a Cuproptosis-Related miRNA Signature in Hepatocellular Carcinoma

Specific classification and new therapeutic targets for neuroendocrine prostate cancer: A patient-based, diagnostic study

Establishment and Validation of Prognostic Nomograms Based on Serum Copper Level for Patients With Early-Stage Triple-Negative Breast Cancer

Contact Info

Product

Resources

About